Top of this page
Skip navigation, go straight to the content

Clinical Studies Overview

Welcome to our

Clinical Studies section

 

UCB's statement on the impact of the COVID-19 outbreak

The evolving COVID-19 pandemic has placed tremendous strain on medical healthcare systems worldwide as they focus on the ongoing extraordinary medical emergency. Taking this into consideration UCB has taken measures to protect our patients and colleagues around the world.

Clinical Studies

In the context of pressurised health systems and with our primary focus on the safety of our patients, UCB has decided to take the following precautionary approach with regards to our clinical studies:

  • To not initiate any new studies.
  • To temporarily halt recruitment into our ongoing clinical studies.  Any exceptions to this are communicated by the program teams to the respective investigators.
  • For all patients who have been recruited into any UCB study, we will continue to focus on the care, access to study medication, clinical evaluations and safety monitoring. Taking a pragmatic approach, UCB is reviewing site visit requirements for regions and sites most impacted by the pandemic.  Any adaptations made will be proactively communicated to participants.

We believe these measures will help lessen the impact on the local health care provision, reduce the risk of patients being unable to receive full and appropriate medical oversight and avoid the inherent risk of study driven hospital/site visits. We will continue to monitor the situation and update guidance to investigators as needed.

Healthcare professionals and patients with questions related to UCB medicines can contact UCBCares / UCB Medical Information teams across the globe. Contact details can be found here.

 

Development of new drugs

UCB researchers seek to understand, prevent and treat diseases.
Clinical studies involving healthy volunteers and patients play a vital role in the development of new drugs.

Patients are enrolled in clinical studies that are consistent with the principles that have their origin in the Declaration of Helsinki and its amendments as well as the laws, regulations and provisions of those countries where humans are enrolled.

 

 



Find out more about a selection of studies

 

Epilepsy in children - "BELLE" study - EP0065

A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects = 1 Month to < 16 Years of Age with Epilepsy.

Recruitment on hold

Status

Nonradiographic axial spondyloarthritis - "BE MOBILE 1" study - AS0010

www.bemobilestudy.com

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis.

Recruitment on hold

Status

Ankylosing spondylitis - "BE MOBILE 2" study - AS0011

www.bemobilestudy.com

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis.

Recruitment on hold

Status

Psoratic arthritis - "BE OPTIMAL" study - PA0010

www.beoptimalstudy.com

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis.

Recruitment on hold

Status

Psoratic arthritis - "BE COMPLETE" study - PA0011

www.becompletestudy.com

A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis.

Recruitment on hold

Status

Drug-resistant Epilepsy - "DUET" study - EP0092

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

Recruitment on hold

Status

Myasthenia Gravis - "MycarinGStudy" - MG0003

www.mycaringstudy.com

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Recruitment on hold

Status

Hidradenitis Suppurativa - "Be Heard" study - HS0003

https://beheardstudy.com

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Recruitment on hold

Status

Hidradenitis Suppurativa - "Be Heard" study - HS0004

https://beheardstudy.com

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Recruitment on hold

Status

Discover more about our clinical studies

Interested in enrolling in our study?

Just contact us



Austria

UCBCares.AT@ucb.com
+43 (0) 1 291 80 08
0800-296176 (freephone)

 


Belgium

UCBCares.BE@ucb.com
+32 2 559 92 00
0800 38 008 (freephone)
www.ucbcares.be



 

Bulgaria

UCBCares.BG@ucb.com
+359 2 962 9933



 

Czech Republic

UCBCares.CZ@ucb.com
+420 221 773 442
800 144 395 (freephone)

 

Denmark

UCBCares.DK@ucb.com
+45 32462480
80 253827 (freephone)


 

Finland

UCBCares.FI@ucb.com
+358 942733300
0800 9 13353 (freephone)


 

France

UCBCares.FR@ucb.com
+33 1 47 29 45 55
0 805 222 949 (freephone)


 

Germany

UCBCares.DE@ucb.com
+49 2173 48 48 48
www.ucbcares.de

 

Greece

UCBCares.GR@ucb.com
+30 21 0997 4200
0080 012 9910 (freephone)


 

Hungary

UCBCares.HU@ucb.com
+36 1 472 5060
06 80 021 486 (freephone)



 

Ireland

UCBCares.IE@ucb.com
+353 1 463 2371
1800 93 00 75 (freephone)
www.ucbcares.co.uk


 

Italy

UCBCares.IT@ucb.com
+39 02 3007 9300
8009-86932 (freephone)
www.ucbcares.it



 

Luxemburg

UCBCares.LU@ucb.com
+32 2 559 92 12
8002 3204 (freephone)



 

Norway

UCBCares.NO@ucb.com
+45 32462482
800-10101 (freephone)



 

Poland

UCBCares.PL@ucb.com
+48 22 596 97 97
00 800 121 68 25 (freephone)



 

Portugal

UCBCares.PT@ucb.com
+351 213 025 300
800-8-56033 (freephone)


 

Slovakia

UCBCares.SK@ucb.com
+421 2 592 020 23
0800 002 566 (freephone)



 

Spain

UCBCares.ES@ucb.com
+34 915 70 06 49
8000-99684 (freephone)
www.ucbcares.es


 

Sweden

UCBCares.SE@ucb.com
+45 32462481
0200 898 671 (freephone)


 

The Netherlands

UCBCares.NL@ucb.com
+31 76 573 1130
0800 3434335 (freephone)



 

UK

UCBCares.UK@ucb.com
+44 1753 777 100
0800 279 3177 (freephone)
www.ucbcares.co.uk


Inspired by patients, driven by science
 
 

Disease resources

Learn more about epilepsy
Rheumatoid arthritis
Learn more about osteoporosis
Learn more about psoriasis
Parkinson's disease
Restless Legs Syndrome
Psoriatic arthritis
Axial Spondyloarthritis
Learn more about juvenile idiopathic arthritis
Learn more about lupus
Crohn's disease